Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Kv3.4 and Kv3.2 are members of the Shaw-related (Kv3) subfamily of voltage-gated potassium channels, characterized by high activation thresholds and exceptionally rapid activation and deactivation kinetics [4, 8, 13]. These properties allow specific neurons, such as fast-spiking interneurons and auditory neurons, to fire action potentials at very high frequencies by ensuring rapid repolarization without increasing the refractory period [8, 13, 31]. While Kv3.2 typically forms delayed rectifier channels, Kv3.4 contributes a fast-inactivating (A-type) component, and their heteromerization fine-tunes the firing properties of central nervous system circuits [10, 13, 15]. Dysregulation of these channels is implicated in several neurological and psychiatric conditions, including Alzheimer's disease, where Kv3.4 is often overexpressed and associated with amyloid-beta toxicity, and schizophrenia, where Kv3.2 dysfunction may disrupt gamma oscillations [18, 25, 26, 33, 34]. Pharmacological targeting of these channels, particularly with positive allosteric modulators like the AUT series, is being explored to restore inhibitory balance in the brain and treat cognitive deficits [31, 32, 33, 37]. However, the widespread expression of Kv3 channels in the brain necessitates careful selectivity to avoid adverse effects such as seizures or motor dysfunction [2, 4, 31].
Positive allosteric modulation of channel opening or blockade of the ion-conducting pore to regulate neuronal excitability and firing frequency.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium voltage-gated channel subfamily C member 4 and member 2 (Kv3.4/Kv3.2).